3 Stocks in Takeover Talks – Week of 11/19

Takeover deals can be a signal of positive market sentiment, indicating that the acquiring company is confident in its growth prospects and is willing to invest in expanding its market share. Such deals often lead to an increase in stock prices as they indicate potential value creation and synergies for the acquiring company. Takeover deals may provide an opportunity for investors to capitalize on market inefficiencies and earn profits through arbitrage strategies, such as buying the target company’s stock at a discount to the offer price and profiting from the price convergence upon deal completion.

Here are three takeover targets for the week –

Astra Space, Inc. – SYM: ASTR
Recent Price: $1.38
Takeover Action: According to Reuters, Astra Space (ASTR) founders Chris Kemp and Adam London proposed to acquire the small rocket maker for $27.8 million, or $1.50 per share in cash.
Description: Astra Space, Inc. designs, tests, manufactures, and operates launch services, and space products and services in the United States of America. It operates through Launch Services and Space Products segments. Astra Space, Inc. was founded in 2016 and is headquartered in Alameda, California.

===
Putin’s War is Driving These Uranium Stocks Higher & Higher

Select small-cap uranium stocks are set to deliver incredible gains in 2023-24 as uranium prices blow past decade highs.

The last time this happened… investors made 10X, 100X… and even 1,000X gains on the best positioned uranium players.

Get the name & trading symbol right now.
===

Gold Resource Corporation – SYM: GORO
Recent Price: $0.27
Takeover Action: Gold Resource Corporation (GORO) announces its Board of Directors has decided to initiate a formal review process, with the assistance of outside financial and legal advisors, to evaluate strategic alternatives including a potential sale of the company.
Description: Gold Resource Corporation engages in the exploration, development, and production of gold and silver projects in Mexico and the United States. The company explores for copper, lead, and zinc deposits. Its principal asset is the 100% owned Back Forty project covering approximately 1,304 hectares located in Menominee county, Michigan. Gold Resource Corporation was founded in 1998 and is headquartered in Denver, Colorado.

===

Jazz Pharmaceuticals plc – SYM: JAZZ
Recent Price: $121.47
Takeover Action: According to Bloomberg, Jazz Pharmaceuticals Plc (JAZZ) is exploring strategic options including a potential sale.
Description: Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company’s lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.